<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02126111</url>
  </required_header>
  <id_info>
    <org_study_id>MBG6043179</org_study_id>
    <nct_id>NCT02126111</nct_id>
  </id_info>
  <brief_title>Efficacy of a Depigmented Extract of Phleum in Local Allergic Rhinitis</brief_title>
  <acronym>GRAMAL</acronym>
  <official_title>Efficacy of a Depigmented Extract of Phleum in the Treatment of Local Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Plaza del Hospital Civil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Laboratorios Leti, S.L.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Plaza del Hospital Civil</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is evaluate the efficacy of a depigmented grass extract in the
      treatment of local allergic rhinitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptoms and medication scores comparison between active and placebo group</measure>
    <time_frame>two years</time_frame>
    <description>Patients were provided a diary to score the severity of their symptoms and the use of rescue medication during 4 weeks in two consecutive springs.
Nasal symptoms of rhinorrhea, nasal congestion, sneezing, nasal itching, and ocular symptoms were recorded using a 4-point categorical scale from 0 to 3 (0: no symptoms, 1:mild, 2:moderate; 3:severe).
The use of rescue medication was recorded in the patient diary according to the following score:
Oral antihistamines (1 tablet = 1 point); intranasal corticosteroids (400mcg/day of beclometasone or equivalent = 1.4 points); and ocular antihistamines (1 dose = 1 point).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response to nasal allergen provocation test with phleum (NAPT-Phl)</measure>
    <time_frame>two years</time_frame>
    <description>The response to NAPT-Phl with increasing concentrations of phleum pratense (0.001-0.01-0.05-0.1 mcg/ml) will be evaluated by nasal symptoms and acoustic rhinometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin prick-test (SPT) with phleum.</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluation of SPT wheal size.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intradermal test (IDT) with phleum</measure>
    <time_frame>2 years</time_frame>
    <description>IDT wheal and erythema size.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaire RQLQ</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Flow cytometry study for determination of IFN-gamma, IL-13, IL-5, IL-8, IL-10, IL-12, IL-2 in peripheral blood and nasal lavage</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of tryptase, eosinophil cationic protein, IgG, IgG4, specific IgE to grass (Phl p1, Phl p5, Phl p7, Phl p12) in peripheral blood and nasal lavage.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>DEPIGOID phleum</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The active treatment arm receive active phleum pollen immunotherapy (Depigoid 100% phleum). Depigmented and polymerized allergen extract of Phleum pollen for subcutaneous injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DEPIGOID Placebo &amp; DEPIGOID Phleum</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This arm receive DEPIGOID Placebo during the first year, and DEPIGOID Phleum during the second year of study.
DEPIGOID Placebo contains the same composition as in the active DEPIGOID Phleum with the only difference being the exclusion of the phleum pollen allergen extract.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DEPIGOID phleum</intervention_name>
    <description>Subcutaneous Immunotherapy with modified extract of Phleum pollen.</description>
    <arm_group_label>DEPIGOID phleum</arm_group_label>
    <arm_group_label>DEPIGOID Placebo &amp; DEPIGOID Phleum</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DEPIGOID Placebo</intervention_name>
    <description>Placebo for subcutaneous administration</description>
    <arm_group_label>DEPIGOID Placebo &amp; DEPIGOID Phleum</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Local allergic rhinitis with sensitization to grass pollen

          -  Skin prick test and serum specific IgE negative to grass pollen.

          -  Positive Nasal allergen provocation test (NAPT) to grass pollen and/or positive nasal
             specific IgE to grass pollen.

          -  Written informed consent

        Exclusion Criteria:

          -  Immunological diseases

          -  Heart diseases that limit the use of adrenaline. For example, severe hypertension or
             treatment with beta-blockers.

          -  Treatment with beta-blockers

          -  Severe psychological disorders

          -  Severe atopic dermatitis

          -  FEV1 &lt; 70% of reference value after treatment

          -  Hypersensitivity or intolerance to excipients and / or medication trial.

          -  Failure to adequately perform diagnostic tests or treatment.

          -  Sensitization to other allergens (perennial or seasonal) with clinical relevance for
             the subject and that may interfere in the evaluation of the response.

          -  Immunotherapy in the 5 years prior to their inclusion in the study.

          -  Pregnant women or at risk of pregnancy and lactating women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miguel Blanca, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Regional Universitario, MÃ¡laga, Spain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Infanta Leonor</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario Carlos Haya</name>
      <address>
        <city>Malaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2014</study_first_submitted>
  <study_first_submitted_qc>April 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2014</study_first_posted>
  <last_update_submitted>November 5, 2016</last_update_submitted>
  <last_update_submitted_qc>November 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Plaza del Hospital Civil</investigator_affiliation>
    <investigator_full_name>Miguel Blanca Gomez</investigator_full_name>
    <investigator_title>Director Allergy Unit</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

